Tag Archive
Preclinical data of Curis’ HSP 90 inhibitor published (News-Medical-Net)
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that preclinical data related to CUDC-305, the company’s Heat Shock Protein (HSP) 90 inhibitor, was published online this week in Molecular Cancer Therapeutics. (more…) Related items Nanotechnology approach may fight problems linked to chemo (Sify News) Biomoda... »
Press conference highlights emerging treatments in pancreatic cancer (News-Medical-Net)
As part of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Thompson will moderate a press conference on emerging treatments in pancreatic cancer on Tuesday, Nov. 17, 2009, in Room 202 of the Hynes Convention Center in Boston, Mass., from 1:00 p.m. to 2:00 p.m. ET. (more…) Related items Emerging Therapies in Pancreatic Cancer Show... »
Emerging Therapies in Pancreatic Cancer Show Promise (Newswise)
As part of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Thompson will moderate a press conference on emerging treatments in pancreatic cancer on Tuesday, Nov. 17, 2009, in Room 202 of the Hynes Convention Center in Boston, Mass., from 1:00 p.m. to 2:00 p.m. ET. (more…) Related items Press conference highlights emerging treatments in... »
Cancer Therapeutics and Nanotherapies sign letter of intent (News-Medical-Net)
Cancer Therapeutics, Inc. (OTCBB: CTHP), an emerging biotechnology business incubator with a specific emphasis on disruptive cancer treatments and nanotechnology, announced today it has signed a letter of intent to acquire another 26 percent interest in NanoTherapies, LLC which would give Cancer Therapeutics a total of 51 percent and controlling interest of NanoTherapies. (get the... »
Cancer Therapeutics Announces Letter of Intent With NanoTherapies, LLC (Marketwire via Yahoo! Finance)
SALT LAKE CITY, UT–(Marketwire - 10/16/09) - Cancer Therapeutics, Inc. (OTC.BB: CTHP - News ), an emerging biotechnology business incubator with a specific emphasis on disruptive cancer treatments and nanotechnology, announced today it has signed a letter of intent to acquire another 26 percent interest in NanoTherapies, LLC which would give Cancer Therapeutics a... »
